The role of vascular endothelial growth factor C in thyroid cancer metastasis
Open Access
- 13 May 2026
- journal article
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (3) , 241-246
Abstract
Background. The vascular endothelial growth factor (VEGF) system includes several ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D and their receptors: VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A primarily signals through VEGFR-2, promoting endothelial cell proliferation, migration, and survival. VEGF-C and VEGF-D are particularly important for lymphangiogenesis via VEGFR-3, which is highly relevant to lymph node metastasis in thyroid cancer. The aim of this study was to compare levels of VEGF in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), as well as in blood plasma and peripheral blood mononuclear cells (PBMC) of patients with PTC. Materials and methods. Postoperative samples of tissue, blood plasma, and cells were obtained from the surgical department of the IEM clinic. The amount of VEGF was determined using enzyme immunoassay kits. Results. VEGF levels in benign neoplasms did not differ from those in CN tissue. There was significant difference between CN tissue and РТС tissues without Mts. The level of VEGF-C in the РТС tissues with Mts was ~ 2.5 times higher than in CN tissues. The high level of VEGF-C was observed in the Mts tissue. The VEGF-C concentration in PTC tissue with Mts exceeded its level in the PTC tissues without Mts by more than 2 times. In plasma and, especially, PBMC of PTC patients, VEGF-C concentration significantly exceeded control levels but there were no differences between specimens with and without Mts. Conclusions. VEGF-C levels in benign thyroid neoplasms did not differ from those in CN tissue. In PTC tissues with Mts, VEGF-C concentrations were significantly elevated compared to CN and PTC tissues without Mts. Our findings reveal significant differences in VEGF concentrations between PTC tissues with and without Mts, which may be useful for predicting metastatic potential of tumor. The level of VEGF-C in plasma and PBMC can become the basis for PTC diagnosis in the preoperative period.Keywords
This publication has 32 references indexed in Scilit:
- Impact of nitrosative stress and endothelial damage on angioinvasive papillary thyroid cancerScientific Reports, 2025
- Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insightsBiomedicine & Pharmacotherapy, 2025
- The role of VEGF in Cancer angiogenesis and tumorigenesis: Insights for anti-VEGF therapyCytokine, 2025
- VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cellsCell Reports, 2023
- The impact of VEGF on cancer metastasis and systemic diseaseSeminars in Cancer Biology, 2022
- VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalkOncogene, 2020
- Steroid receptor coactivator-1 interacts with NF-κB to increase VEGFC levels in human thyroid cancerBioscience Reports, 2018
- A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathwayBiomaterials, 2017
- Serum Vascular Endothelial Growth Factor C Correlates With Lymph Node Metastases and High-Risk Tumor Profiles in Papillary Thyroid CarcinomaAnnals of Surgery, 2008
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976